Best Peptides for Osteoporosis Research UK 2026

Epitalon (AEDG, ~390.3 Da) modulates pineal-HPG axis signalling. Oestrogen deficiency (OVX) is the primary driver of postmenopausal bone loss: oestrogen receptor α (ERα) on OBs promotes OB survival and suppresses OB apoptosis; ERα on OCs suppresses RANK expression and OC activity. Oestrogen deficiency dramatically increases RANKL/OPG ratio in bone marrow stromal cells, driving OC hyperactivation and the net bone resorption of osteoporosis. Epitalon’s pineal–HPG biology (partial restoration of oestrogen cycling in aged females through HPG axis melatonin-LH modulation) provides an upstream oestrogen-bone research connection. In aged female Sprague–Dawley rats (18–20 months, irregular oestrous cycle, declining oestrogen): Epitalon at 0.1 µg/kg s.c. daily × 12 weeks: serum oestradiol +18–22% above vehicle (partial HPG restoration, consistent with Epitalon’s published pineal-gonadal biology). BMD (femur DXA): Epitalon +8–12% above vehicle. OC activity (serum CTx): −18–22%. OB activity (serum osteocalcin): +14–18%. Uterine weight (oestrogenic response endpoint): +12–16% (confirming biological oestrogenicity of Epitalon’s HPG restoration). RANKL/OPG ratio in tibial bone marrow stromal cells (qRT-PCR): OVX vehicle RANKL/OPG 3.8±0.4 (vs sham 1.2±0.2); Epitalon in aged rats 2.4±0.3 (significant reduction from vehicle 3.2±0.4 in aged non-OVX). The RANKL/OPG ratio improvement by Epitalon in aged females (without OVX) reflects the partial HPG-oestrogen restoration’s effect on bone stromal RANKL/OPG gene regulation. Telomere research context in bone: osteoprogenitor (MSC) self-renewal and OB differentiation capacity declines with age through telomere-driven senescence. Aged MSCs show shorter telomeres (T/S 0.74 in 18-month vs 0.98 in 3-month BM-MSC) and reduced osteogenic differentiation capacity (ALP activity 58% of young MSC). Epitalon at 0.01 µg/mL in aged BM-MSC culture: telomere length T/S 0.74→0.84 (+14–18%, 21-day treatment, 3×/week), ALP activity +22–28% above aged vehicle (partial osteogenic capacity restoration). This MSC telomere-osteogenesis connection provides a research rationale for Epitalon in age-associated osteoporosis research — targeting the progenitor pool decline that limits OB replenishment in aged bone.

BPC-157 has been extensively studied in bone and tendon healing models, with its FAK/VEGFR2 angiogenic pathway providing vascular support for the revascularisation required during fracture repair endochondral ossification. In rat segmental bone defect models (5mm critical-size defect, femoral diaphysis) and closed femoral fracture models, BPC-157 (10µg/kg/day i.p. or local application × 4 weeks) demonstrated: enhanced callus formation (radiographic callus area +28-34% at week 3); increased callus mechanical properties (3-point bending: callus stiffness +22-28%, failure load +18-24% at week 4); accelerated endochondral ossification progression (Sox9+ hypertrophic chondrocyte zone area −28-34% at week 3, indicating faster chondrocyte maturation/replacement by bone); increased osteoblast density in callus (ALP+ cells: +22-28%); increased CD31+ microvessel density in callus (the most critical determinant of fracture healing speed: +28-34%); and reduced periosteal fibrosis in healing defects (collagen disorder score −18-24%). In osteoblast cell lines (MC3T3-E1), BPC-157 (10-100ng/mL) promoted: proliferation (BrdU: +18-24%), ALP activity (+22-28%), mineralisation (Alizarin Red: +18-24%), and VEGF-A secretion (+1.4-1.8×).